Insights

Innovative Therapeutics Sylentis specializes in gene silencing technologies for ophthalmologic conditions like glaucoma and dry eye syndrome, presenting opportunities to collaborate with biotech firms or clinics seeking cutting-edge treatments.

Strategic Parent-Group As a wholly owned subsidiary of PharmaMar, Sylentis benefits from strong financial backing and research synergies, suggesting potential to expand its product portfolio and explore new therapeutic areas with affiliates or partners.

Leadership Expansion Recent appointment of a new CEO indicates ongoing strategic growth and innovation, which could open doors for investors or partners interested in pioneering biotech leadership.

Market Position With a revenue range of one to ten million dollars and a focus on specialized gene therapies, Sylentis offers opportunities to pharmaceutical and biotech companies looking to license or co-develop ophthalmic gene silencing treatments.

Technology Stack Utilizing modern web and analytics tools, Sylentis demonstrates a digital presence that can facilitate partnerships, drug licensing negotiations, and outreach to research organizations engaged in biotech innovation.

Similar companies to SYLENTIS

SYLENTIS Tech Stack

SYLENTIS uses 8 technology products and services including WordPress, Microsoft 365, Google Fonts API, and more. Explore SYLENTIS's tech stack below.

WordPress
Content Management System
Microsoft 365
Email
Google Fonts API
Font Scripts
spin.js
Javascript Frameworks
Isotope
Javascript Libraries
DPD
Logistics
Bootstrap
UI Frameworks
Google Analytics
Web Analytics

Media & News

Sylentis hires Andreas Segerros as Chief Executive Officer.
Sylentis, a PharmaMar group company, appoints Andreas Segerros as Chief Executive Officer.
May 28, 2024 | pharmamar.com

SYLENTIS's Email Address Formats

SYLENTIS uses at least 1 format(s):

SYLENTIS Email Formats	Example	Percentage
FLast@sylentis.com	JDoe@sylentis.com	100%

Frequently Asked Questions

Where is SYLENTIS's headquarters located?

SYLENTIS's main headquarters is located at 2 c Santiago Grisolía Humanes de Madrid, Community of Madrid 28760 Spain. The company has employees across 1 continents, including Europe.

What is SYLENTIS's phone number?

You can contact SYLENTIS's main corporate office by phone at

+34-918-04-7****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is SYLENTIS's official website and social media links?

SYLENTIS's official website is sylentis.com and has social profiles on LinkedIn Crunchbase.

What is SYLENTIS's SIC code NAICS code?

SYLENTIS's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does SYLENTIS have currently?

As of April 2026, SYLENTIS has approximately 60 employees across 1 continents, including Europe. Key team members include Chief Executive Officer: A. S.Head Of Clinical Operations: A. B.Head Of Regulatory Affairs: V. R.. Explore SYLENTIS's employee directory with LeadIQ.

What industry does SYLENTIS belong to?

SYLENTIS operates in the Biotechnology Research industry.

What technology does SYLENTIS use?

SYLENTIS's tech stack includes WordPressMicrosoft 365Google Fonts APIspin.jsIsotopeDPDBootstrapGoogle Analytics.

What is SYLENTIS's email format?

SYLENTIS's email format typically follows the pattern of FLast@sylentis.com. Find more SYLENTIS email formats with LeadIQ.

When was SYLENTIS founded?

SYLENTIS was founded in 2006.

SYLENTIS

Q: What is SYLENTIS's official website and social media links?

SYLENTIS's official website is sylentis.com. SYLENTIS has social profiles on LinkedIn.

Q: How many employees does SYLENTIS have currently?

SYLENTIS has approximately 60 employees.

Q: What technology does SYLENTIS use?

SYLENTIS's tech stack includes Essential Addons for Elementor, spin.js, DPD, MySQL, Ubuntu.

Q: What is SYLENTIS's NAICS code?

SYLENTIS's NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Biotechnology ResearchCommunity of Madrid, Spain51-200 Employees

Sylentis is an European biotechnological company founded in 2006. Sylentis focuses on researching new therapeutic approaches based on gene silencing. Our company is specialised in developing ophtalmologic   therapies via interference RNA, a powerful tool for rational drug design.

Most advanced product of the company are treatments for glaucoma and dry eye syndrome.

Sylentis is a wholly owned member of PharmaMar (www.pharmamar.com)

Company Overview

Headquarters: 2 c Santiago Grisolía Humanes de Madrid, Community of Madrid 28760 Spain
Phone number: +34-918-04-7****
Website: sylentis.com
SIC Code: 8733 - Noncommercial Research Organizations
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2006
Employees: 51-200